Medical Health & Life Science Research News

Recent Study - Engineered T Cells market analysis and forecast till 2023

Allergic Rhinitis

The “Engineered T Cells Market ” is an in-depth analysis of the market with a focus on the global trend. The report goals to provide an overview of the Engineered T Cells Market with detailed segmentation by product, type, application, and geography

T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers.

The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.

Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth.

However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.

Know More| Download Sample Copy at: www.premiummarketinsights.com/sample/AMR00013682

KEY PLAYERS PROFILED IN THE REPORT

Autolus Limited
Bellicum Pharmaceuticals, Inc.
Cell Medica
Elli Lilly and Company
Gilead Sciences, Inc.
Juno Therapeutics
Novartis AG
Oxford Biomedica
Pfizer Inc.

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells.

By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on end user assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Inquire More About at: www.premiummarketinsights.com/inquiry/AMR00013682

News From

Premium Market InsightsPremium Market Insights
Category: Market Research Publishers and RetailersCompany about: Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
This email address is being protected from spambots. You need JavaScript enabled to view it.